Sichuan Baili Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Nifekalant hydrochloride

Phase 3 pipeline

• BL-B01D1 · Diabetes
  BL-B01D1 is a small molecule drug that targets the SGLT2 receptor.
• BL-M07D1
  BL-M07D1 is a small molecule drug that targets the molecular target.
• Liposomal doxorubicin, Paclitaxel or Topotecan · Oncology
  This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells.
• Pemetrexed+Cisplatin or Carboplatin · Oncology
  Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while cisplatin or carboplatin cross-link DNA, together disrupting cancer cell replication and survival.
• SI-B001 · Diabetes
  SI-B001 is a small molecule drug that targets the SGLT2 receptor.

Phase 2 pipeline

• AP or TP · Psychiatry
  Selective serotonin reuptake inhibitor
• BL-B01D1 for Injection
  BL-B01D1 for Injection is a drug that works by targeting a specific molecular pathway.
• SI-B003

Phase 1 pipeline

• BL-B16D1
• BL-M02D1
• BL-M08D1
• BL-M09D1
• BL-M17D1
• BL-M24D1
• GNC-035
• GNC-038
• GNC-039
• GNC-077
• Lutetium [177Lu] BL-ARC001
• SI-F019

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI brief
• Sichuan Baili Pharmaceutical Co., Ltd. pipeline updates RSS